Indeed, in the Transthyretin Amyloidosis Outcomes Survey (THAOS) Registry, more than one-third of asymptomatic TTR gene mutation carriers developed ATTRv amyloidosis within a median of approximately 2 years of enrolment [13]. The gene discussed is TTR; the disease is amyloidosis.